Flash FinanceUS
Market open S&P 5007,376.86+0.31% Nasdaq24,579.42+1.09% Dow 3051,285.73-0.46% Russell 20002,754.11+0.89% Nasdaq-10026,989.99+1.35% MidCap 4003,602.50+0.56% SmallCap 6001,673.98+0.05% VIX25.64-9.01% 10Y Yield4.86+0.45% Close of Nov 06, 2026
AI brief of an SEC Form 8-K · Rein Therapeutics, Inc. (RNTX)

Rein Therapeutics Gets Nasdaq Notice for Bid Price Below $1.00

Negative Impact 4 of 5 legal/regulatory Written later

Rein Therapeutics received a Nasdaq notice on August 21, 2026, because its common stock closed below $1.00 per share over the previous 30 consecutive trading days. The company has until February 17, 2027 to regain compliance, and Nasdaq says it will start suspension and delisting procedures if compliance is not regained in time.

Key points

  • Notice received from Nasdaq on August 21, 2026 under Rule 5550(a)(1), the minimum $1.00 bid price standard
  • Compliance deadline is February 17, 2027, 180 days from the notice date
  • Regaining compliance requires a closing bid price of at least $1.00 for a minimum of 10 consecutive business days
  • Filing states there is no assurance of additional time after the initial 180-day period

The filing

CompanyRein Therapeutics, Inc. (RNTX)
Form8-K, current report
Filed with the SECAug 27, 2026, 4:05 PM ET
Accession number0001193125-26-371260

Items reported: 3.01 Delisting / Listing Rule Notice

Read the filing on SEC.gov ↗

Written by AI on Nov 9, 2026, 10:08 AM ET, from this filing only. Written later: this filing was briefed after the fact, when past filings were added to the site, so the brief may be read with hindsight; the filing itself is the record of what was known on August 27, 2026.

Briefs are written by AI from the filing text and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the AI's reading of the filing for shareholders, not a price forecast. Not investment advice.